EGFR and lung adenocarcinoma: In total, these findings suggest that chronic EGFR inhibition in EGFR mutant lung adenocarcinomas can lead to the development of cancers that adopt the genetic, histologic, expression and drug sensitivity profiles of classical SCLC.